Geron (GERN) Revenue Growth (1y) (2011 - 2026)
Powered by 
Analysis
Geron (GERN) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 9.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 10.18% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 12.45% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 16.73% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 59.71% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 2.11% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 66.86% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.42% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 17.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.22% |
| Mar 31, 2026 | 30.89% |
| Dec 31, 2025 | 45.50% |
| Sep 30, 2025 | 67.05% |
| Jun 30, 2025 | 5,459.64% |
| Mar 31, 2025 | 12,927.30% |
| Dec 31, 2024 | 260,600.00% |
| Sep 30, 2024 | 17,138.41% |
| Jun 30, 2024 | 2,941.38% |
| Mar 31, 2024 | 1,347.62% |
| Dec 31, 2023 | -77.67% |
| Sep 30, 2023 | -44.78% |
| Jun 30, 2023 | -60.27% |
| Mar 31, 2023 | -82.93% |
| Dec 31, 2022 | -90.10% |
| Sep 30, 2022 | 172.48% |
| Jun 30, 2022 | -31.78% |
| Mar 31, 2022 | -10.22% |
| Dec 31, 2021 | 1,980.00% |
| Sep 30, 2021 | 0.93% |